Reply to R. Sun et al
- 1 April 2023
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (10), 1953-1954
- https://doi.org/10.1200/jco.23.00063
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJournal of Clinical Oncology, 2023
- Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and RecommendationsJNCI Cancer Spectrum, 2022
- Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trialGynecologic Oncology, 2021
- Restricted Mean Survival Time: An Obligatory End Point for Time-to-Event Analysis in Cancer Trials?Journal of Clinical Oncology, 2016
- Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 TrialGynecologic Oncology, 2014
- Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival AnalysisJournal of Clinical Oncology, 2014
- Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Medical Research Methodology, 2013
- Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancerGynecologic Oncology, 2013
- The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubtStatistics in Medicine, 2011
- Statistical Considerations in the Intent-to-Treat PrincipleControlled Clinical Trials, 2000